[Form 4] Gossamer Bio, Inc. Insider Trading Activity
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo reported an award of 181,250 performance stock units on 10/01/2025. The award is a non‑cash grant that will vest in full upon the earlier of: approval of a new drug application for seralutinib or a change in control, provided vesting occurs on or before the fourth anniversary of the grant and the reporting person remains in continuous service. Following the reported grant, Mr. Giraudo beneficially owns 273,987 shares directly and 480,010 shares indirectly through a family trust, for combined reported beneficial ownership disclosed on the form.
Gossamer Bio, Inc. (GOSS) il Chief Operating and Financial Officer Bryan Giraudo ha riportato un'assegnazione di 181.250 unità azionarie di performance il 01/10/2025. L'assegnazione è un grant non monetario che si maturerà integralmente al più presto fra: l'approvazione di una nuova domanda di farmaco per seralutinib o un cambio di controllo, a condizione che la vesting avvenga entro il quarto anniversario del grant e che la persona che segnala rimanga in servizio continuo. A seguito dell'assegnazione riportata, il signor Giraudo detiene beneficiariamente 273.987 azioni direttamente e 480.010 azioni indirettamente tramite una family trust, per una proprietà beneficiaria combinata riportata nel modulo.
Gossamer Bio, Inc. (GOSS) el Director de Operaciones y Financiero Bryan Giraudo informó sobre una asignación de 181.250 unidades de acciones de desempeño el 01/10/2025. La asignación es una concesión no monetaria que vencerá por completo al primero de: la aprobación de una nueva solicitud de fármaco para seralutinib o un cambio de control, siempre que la vigencia ocurra en o antes del cuarto aniversario de la concesión y la persona que reporta se mantenga en servicio continuo. Tras la concesión informada, el Sr. Giraudo posee en beneficio 273.987 acciones directamente y 480.010 acciones indirectamente a través de un fideicomiso familiar, para una titularidad benificiosa combinada revelada en el formulario.
Gossamer Bio, Inc. (GOSS) 최고운영책임자 겸 최고재무책임자 Bryan Giraudo는 181,250개의 성과주식 유닛을 2025년 10월 1일에 보고했습니다. 이 수상은 비현금 보상으로, seralutinib의 신약승인 또는 경영권 변경 중 먼저 도래하는 시점에 전부 vesting되며, 보상권은 보조가제의 네 번째 기념일까지의 vesting을 필요로 하고 보고자는 지속적으로 근무해야 합니다. 보고된 수상 이후, Giraudo 씨는 직접 273,987주와 가족 신탁을 통해 간접적으로 480,010주를 보유하게 되며, 양식에 공시된 합계 보유지분은 이와 같습니다.
Gossamer Bio, Inc. (GOSS) le directeur des opérations et des finances Bryan Giraudo a signalé une attribution de 181 250 unités d’actions de performance le 01/10/2025. L’attribution est une subvention non monétaire qui sera entièrement acquise à la première éventualité entre: l’approbation d’une nouvelle demande de médicament pour le seralutinib ou un changement de contrôle, à condition que l’acquisition ait lieu au plus tard le quatrième anniversaire de la subvention et que la personne déclarante demeure en service continu. Suite à l’attribution signalée, M. Giraudo détient bénéficiairement 273 987 actions directement et 480 010 actions indirectement par le biais d’un trust familial, pour une propriété bénéficiaire combinée telle qu’indiquée dans le formulaire.
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo meldete eine Zuteilung von 181.250 Performance-Aktieneinheiten am 01.10.2025. Die Zuteilung ist eine nicht geldwerte Gewährung, die vollständig vestet, sobald früher einreichen einer neuen Arzneimittelanmeldung für seralutinib vorliegt oder eine Change in Control erfolgt, vorausgesetzt die Vesting erfolgt am oder vor dem vierten Jahrestag der Gewährung und der meldende Person bleibt ununterbrochen im Dienst. Nach der gemeldeten Zuteilung besitzt Herr Giraudo vorteilhaft 273.987 Aktien direkt und 480.010 Aktien indirekt über einen Familienstamm, für eine kombinierte gemeldete wirtschaftliche Eigentümerschaft gemäß dem Formular.
Gossamer Bio, Inc. (GOSS) أبلغ المدير التنفيذي للعمليات والشؤون المالية بريان جيرادو عن منحة قدرها 181,250 وحدة أسهم أداء في 01/10/2025. المنحة هي منحه غير نقدية ستكتمل عند أقرب حدث وهو: الموافقة على طلب دواء جديد لـ seralutinib أو تغير في السيطرة، بشرط أن يحدث vesting في أو قبل السنة الرابعة من المنحة وأن يبقى الشخص المبلغ عنه في الخدمة المستمرة. عقب المنحة المبلغ عنها، يمتلك السيد جيرادو فائدة مباشرة من 273,987 سهمًا و< b>480,010 سهمًا بشكل غير مباشر من خلال صندوق عائلي، لإجمالي الملكية المفيدة المبلغ عنها في النموذج.
Gossamer Bio, Inc. (GOSS) 首席运营官兼首席财务官 Bryan Giraudo 报告称获授 181,250 股权绩效单位，日期为 2025/10/01。该授予属于非现金 grant，将在以下较早者时全部归属：获得新药申请对 seralutinib 的批准，或发生控股变更，前提是归属在授予日后的第四周年前或当日发生，且报告人持续在职。在该授予后，Giraudo 先生直接持有 273,987 股，间接通过家庭信托持有 480,010 股，总计披露的受益所有权。
- 181,250 performance stock units granted to align executive incentives with seralutinib approval
- Reporting person holds 273,987 shares directly and 480,010 indirectly, indicating significant insider stake
- None.
Insights
Insider received performance-based equity tied to a regulatory milestone.
The award of 181,250 performance stock units vests only on the earlier of seralutinib new drug application approval or a change in control, with a four‑year outer vesting limit and a continuous service requirement. This structure aligns executive compensation with a specific regulatory outcome rather than time‑based tenure.
The filing names Mr. Bryan Giraudo as COO/CFO and shows direct ownership of 273,987 shares and indirect ownership of 480,010 shares, reflecting his reported economic exposure to the company.
Grant is a performance stock unit conditioned on a product approval or change in control.
The instrument is a performance stock unit award granted on 10/01/2025 with no cash price paid, per the form. Vesting is binary and event‑driven, tying potential dilution to a single material milestone: NDA approval of seralutinib or change in control within four years.
Gossamer Bio, Inc. (GOSS) il Chief Operating and Financial Officer Bryan Giraudo ha riportato un'assegnazione di 181.250 unità azionarie di performance il 01/10/2025. L'assegnazione è un grant non monetario che si maturerà integralmente al più presto fra: l'approvazione di una nuova domanda di farmaco per seralutinib o un cambio di controllo, a condizione che la vesting avvenga entro il quarto anniversario del grant e che la persona che segnala rimanga in servizio continuo. A seguito dell'assegnazione riportata, il signor Giraudo detiene beneficiariamente 273.987 azioni direttamente e 480.010 azioni indirettamente tramite una family trust, per una proprietà beneficiaria combinata riportata nel modulo.
Gossamer Bio, Inc. (GOSS) el Director de Operaciones y Financiero Bryan Giraudo informó sobre una asignación de 181.250 unidades de acciones de desempeño el 01/10/2025. La asignación es una concesión no monetaria que vencerá por completo al primero de: la aprobación de una nueva solicitud de fármaco para seralutinib o un cambio de control, siempre que la vigencia ocurra en o antes del cuarto aniversario de la concesión y la persona que reporta se mantenga en servicio continuo. Tras la concesión informada, el Sr. Giraudo posee en beneficio 273.987 acciones directamente y 480.010 acciones indirectamente a través de un fideicomiso familiar, para una titularidad benificiosa combinada revelada en el formulario.
Gossamer Bio, Inc. (GOSS) 최고운영책임자 겸 최고재무책임자 Bryan Giraudo는 181,250개의 성과주식 유닛을 2025년 10월 1일에 보고했습니다. 이 수상은 비현금 보상으로, seralutinib의 신약승인 또는 경영권 변경 중 먼저 도래하는 시점에 전부 vesting되며, 보상권은 보조가제의 네 번째 기념일까지의 vesting을 필요로 하고 보고자는 지속적으로 근무해야 합니다. 보고된 수상 이후, Giraudo 씨는 직접 273,987주와 가족 신탁을 통해 간접적으로 480,010주를 보유하게 되며, 양식에 공시된 합계 보유지분은 이와 같습니다.
Gossamer Bio, Inc. (GOSS) le directeur des opérations et des finances Bryan Giraudo a signalé une attribution de 181 250 unités d’actions de performance le 01/10/2025. L’attribution est une subvention non monétaire qui sera entièrement acquise à la première éventualité entre: l’approbation d’une nouvelle demande de médicament pour le seralutinib ou un changement de contrôle, à condition que l’acquisition ait lieu au plus tard le quatrième anniversaire de la subvention et que la personne déclarante demeure en service continu. Suite à l’attribution signalée, M. Giraudo détient bénéficiairement 273 987 actions directement et 480 010 actions indirectement par le biais d’un trust familial, pour une propriété bénéficiaire combinée telle qu’indiquée dans le formulaire.
Gossamer Bio, Inc. (GOSS) Chief Operating and Financial Officer Bryan Giraudo meldete eine Zuteilung von 181.250 Performance-Aktieneinheiten am 01.10.2025. Die Zuteilung ist eine nicht geldwerte Gewährung, die vollständig vestet, sobald früher einreichen einer neuen Arzneimittelanmeldung für seralutinib vorliegt oder eine Change in Control erfolgt, vorausgesetzt die Vesting erfolgt am oder vor dem vierten Jahrestag der Gewährung und der meldende Person bleibt ununterbrochen im Dienst. Nach der gemeldeten Zuteilung besitzt Herr Giraudo vorteilhaft 273.987 Aktien direkt und 480.010 Aktien indirekt über einen Familienstamm, für eine kombinierte gemeldete wirtschaftliche Eigentümerschaft gemäß dem Formular.
FAQ
What transaction did Bryan Giraudo report on Form 4 for GOSS?
What are the vesting conditions for the awarded performance stock units?
How many shares does the reporting person beneficially own after the transaction?
What role does the reporting person hold at Gossamer Bio?
When was the Form 4 filed and signed by the attorney-in-fact?
